 WILMINGTON, Del., March 03, 2021 GLOBE NEWSWIRE -- Prelude Therapeutics Inc. Prelude, the Company, we, our Nasdaq: PRLD, a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences: 